ArticleJournal of thoracic disease2026
Percutaneous mechanical thrombectomy using the AcoStream thrombus aspiration system for intermediate-high-risk pulmonary embolism.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intermediate-high-risk pulmonary embolism (PE), characterized by right ventricular (RV) dysfunction and elevated cardiac biomarkers without hemodynamic instability, carries a substantial risk of clinical deterioration. While catheter-directed thrombolysis (CDT) is effective, it carries inherent bleeding risks. Large-bore mechanical thrombectomy (MT) has emerged as a promising alternative, but its real-world efficacy and safety require further validation. Therefore, we retrospectively reviewed consecutive patients with acute intermediate-high-risk PE who underwent MT using the AcoStream system. Methods: Between July 2021 and February 2025, 45 patients diagnosed with acute intermediate-high-risk PE who underwent MT using the AcoStream system were retrospectively analyzed. Efficacy outcomes included immediate and early improvements in the angiographic total Miller index, pulmonary artery systolic pressure (PASP), gas exchange (PaO Results: Following the procedure, the median total Miller index decreased significantly from 16.00 [interquartile range (IQR), 15.00, 18.00] to 6.00 (IQR, 5.00, 8.00) (P<0.001), accompanied by an immediate reduction in PASP from 46.00 mmHg (IQR, 41.00, 50.00) to 30.00 (IQR, 26.00, 32.00) mmHg (P<0.001). Gas exchange and physiological parameters improved profoundly, with the PaO2/FiO2 ratio increasing from 260.00 (IQR, 204.00, 286.00) to 381.00 (IQR, 367.00, 395.00) mmHg (P<0.001), heart rate decreasing from 104.00 to 80.00 bpm (P<0.001), and lactate dropping from 1.90 to 1.50 mmol/L (P<0.001). In the subgroup with echocardiographic data (n=34), the median RV/LV ratio was 0.91 (IQR, 0.87, 0.97) at 48 hours post-procedure. No major bleeding events (0.0%) occurred during hospitalization or follow-up. CRNMB occurred in 3 patients (6.7%) and was managed conservatively. Conclusions: MT using the AcoStream system was associated with favorable short-term procedural and hemodynamic observations in patients with acute intermediate-high-risk PE. Given the observational design and lack of a comparator group, these findings should be considered hypothesis-generating and require confirmation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.